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ABSTRACT
Background and Objectives: Risk factors predisposing to foot ulceration in diabetic subjects are multiple. Long 
duration of diabetes mellitus is a major risk factor, likewise peripheral neuropathy (PN), which globally, is 
recognized as the commonest risk factor for foot disease in diabetic subjects. 
Objectives: To evaluate the effect of duration of diabetes mellitus on peripheral neuropathy using the United 
Kingdom Screening Test (UKST) Scoring System, Bio-thesiometry and Aesthesiometry, in Nigerian diabetic 
subjects without current or previous foot ulceration.
Subjects and methods: One hundred and twenty (120) diabetes mellitus (DM) subjects with and without symptoms 
of peripheral neuropathy receiving care at the medical outpatient department (MOPD) and the diabetic clinic of the 
Nnamdi Azikiwe University Teaching Hospital Nnewi, Nigeria, were recruited consecutively as they presented. 
Data collected included subjects age (years), gender, age at first diagnosis of DM, duration of DM (years) and 
baseline fasting venous plasma glucose. The United Kingdom Screening Test (UKST) symptom score was used to 
separate the participants into two groups  those with symptoms of PN and those without and the subjects further 
assessed by three methods  the UKST Signs score, Bio-thesiometry and Aesthesiometry  to determine the presence 
of PN. 
Results: Among the 120 diabetic participants, 83(69.2%) had neuropathic symptoms (the symptomatic participants) 
while 37(30.8%) were asymptomatic (the asymptomatic participants). The different methods of diagnosing PN 
increasingly detected PN with increasing duration of diabetes. For the symptomatic group, the UKST method 
detected PN least in those with duration of DM <5 years (73.9%) and 100.0% in those with duration of DM >15 years 
while for the asymptomatic group, it detected PN in 25.0% of those with duration of DM <5 years, and 100.0% for 
those with duration of DM >15 years. For the symptomatic group, Aesthesiometry detected PN in 65.2% of those 
with duration of DM <5 years and 91.7% in those with duration of DM >15 years. For the asymptomatic group, it 
detected PN in 29.2% of those with duration of DM <5 years and 100.0% in those with duration of DM >15 years. 
Likewise, for the symptomatic group, Bio-thesiometry detected PN in 47.8% of those with duration of DM <5 years 
and 100.0% in those with duration of DM >15 years. For the asymptomatic group, it detected PN in 16.7% of those 
with duration of DM <5 years and 100.0% in those with duration of DM >15 years.
Conclusion: Long duration of diabetes mellitus and peripheral neuropathy are risk factors for foot complication in 
Nigerians with diabetes mellitus. Diabetic subjects with long duration of diabetes (>10 years) almost always have 
associated peripheral neuropathy, and should be recognized as a special group at high risk for foot disease from DM. 
Specific preventive programs should target this group to reduce the rate of avoidable loss of limbs to diabetes. 
Key Words: Diabetic foot ulceration, peripheral neuropathy, United Kingdom Screening Test, Aesthesiometry, Bio-
thesiometry.                                                                                                                       
INTRODUCTION
Risk factors predisposing to foot ulceration in diabetic 
subjects are multiple. Long duration of diabetes 
mellitus (>10 years) is a major risk factor for foot 
disease in diabetic subjects and is frequently associated 
1with neuropathy in diabetic subjects.  However, 
duration may not reflect the true duration of the disease, 
rather it may reflect really the time since diagnosis as
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NIDDM onset may precede its diagnosis by several 
2 years.
Generally, for duration of diabetes mellitus (DM) up to 
10 years or less, the majority of patients do not have 
neuropathy but for duration greater than 10 years, 
3majority of patients have neuropathy.  In the Pima 
2Indian study,  duration of DM was a significant risk 
factor for amputation, even after controlling for age and 
sex.
Peripheral nerve damage is a common complication of 
4 DM and worldwide is recognized as the commonest
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24treatment with oral hypoglycemic agents or insulin ) 
and newly diagnosed diabetic patients as defined by the 
World Health Organization (WHO) 1999 Diagnostic 
25Criteria.  None of the study subjects had a previous or a 
current foot ulcer at the time of the study. Data collected 
included subjects age (years), gender, age at first 
diagnosis of DM and duration of DM (years). Baseline 
fasting venous plasma glucose was estimated by the 
Glucose Oxidase Method and read colorimetrically in 
the chemical pathology laboratory of the NAUTH, 
Nnewi.
A clinical scoring system - the United Kingdom 
26Screening Test (UKST)  was applied to each 
participant and used to screen/score for symptoms of 
peripheral sensory neuropathy, to objectively separate 
the symptomatic from the asymptomatic participants. 
Since the UKST instrument is a screening instrument 
previously unapplied to local (Nigerian) studies 
involving diabetic patients, a pretest questionnaire was 
initially developed based on the UKST symptoms score 
only and administered to 40 diabetic patients with and 
without foot complications, recruited randomly from 
the study center to assess performance and applicability 
of this screening instrument for PN among Nigerian 
diabetic patients. All 40(100%) subjects gave responses 
easily scored using the UKST symptoms score 
confirming the applicability of the screening tool. The 
subjects of the pretest trial were excluded from the 
study population proper.
The symptoms of PN scored (see Table1) were the 
abnormal sensations felt by the patients in the feet/leg 
namely:
: Burning, numbness or tingling, which score 2 
points 
:            Fatigue, aching or cramping, which score 1 
point.
The impact of site of discomfort, time of worst 
symptoms, night-time awakening and 
alleviating factors contributed further scores. 
Maximum symptoms score was 9 graded as 
follows: 
: Normal (no PN) 0-2
: Mild PN 3-4
: Moderate PN 5-6
: Severe PN 7-9
The criteria for symptomatic PN was presence of 
moderate (5-6) or severe (7-9) symptom 
score, a criterion chosen to eliminate the risk factor of 
overestimation of symptomatic PN by 
including mild symptom scores. Mild symptoms scores 
may be transient and may also occur 
normally in the general (non-diabetic) population with 
increasing age.  
Following separation of the study population into 
symptomatic and asymptomatic groups, the study 
population was further assessed with three objective 
instruments  the UKST signs score, Bio-Thesiometry 
and Aesthesiometry  to evaluate the presence of 
peripheral neuropathy as a risk factor for foot ulceration
5-8Risk factor for foot disease among diabetic subjects.  It 
is detected by screening for typical symptoms and 
signs. The exact pathogenesis of diabetic peripheral 
neuropathy (PN) is unclear, and like diabetes mellitus 
itself, is probably a heterogeneous disorder not fully 
9explained by a single pathogenic mechanism.  Early 
lesions may arise from exposure of peripheral nerves to 
hyperglycaemia. Subsequently, accumulation of 
sorbitol and fructose generated from glucose shunted 
into the polyol pathway by aldose reductase and 
sorbitol dehydrogenase together with deficiencies of 
myoinositol and diacylglycerol all may combine as 
potent metabolic factors responsible for structural 
10-breakdown of nerves and slowed conduction velocity.
12 13 Findings of prominent microangiopathy  and 
14multifocal fibre loss  pathologically support possible 
vascular causes for PN. Damage to endothelial cells by 
advanced glycosylation endproducts (AGEs) cause 
decreased endothelial nitric oxide and prostacyclin 
production, resulting in vasoconstriction, platelet 
aggregation and disrupted blood nerve barriers. 
Recently, attention has focused on the role of reduced 
15,16nerve growth factor levels as a cause of diabetic PN.
Distal symmetric polyneuropathy involving sensory, 
motor and autonomic nerve fibres is the most common 
17,18form of neuropathy in DM subjects.  Ulcers 
commonly result from sensory neuropathy which 
blunts protective pain sensation, chronic motor 
neuropathy with atrophy of the small intrinsic muscles 
of the foot which distorts the normal anatomy and bio-
mechanics of the foot with abnormal point  pressure 
19loading and mal-distribution of pressure,  and 
autonomic neuropathy which impairs  the  
20-23microcirculation and the integrity of the skin.
OBJECTIVE
This study seeks to evaluate the effects of duration of 
DM on peripheral neuropathy using the United 
Kingdom Screening Test (UKST) Scoring System, 
Bio-thesiometry and Aesthesiometry in Nigerian 
diabetic patients without current or previous foot 
ulceration.
METHODOLOGY 
The study was carried out at the Nnamdi Azikiwe 
University Teaching Hospital (NAUTH) Nnewi, a 268 
bed tertiary health institution in Anambra State, South 
Eastern Nigeria. While not having a strict catchment 
area, most patients come from Anambra State with a 
population of about 3 million. Referrals also come from 
a large catchment area of other neighboring states in 
South-Eastern and South-South Nigeria including Imo, 
Abia, Enugu, Cross-River, Akwa-Ibom, Ebonyi, Rivers 
and Delta states. 
Following informed consent and ethical approval, 120 
diabetic participants were recruited consecutively as 
they presented to the medical outpatient department 
(MOPD) and diabetic clinic of the Nnamdi Azikiwe 
University Teaching Hospital (NAUTH) Nnewi. They 
included known diabetic patients (currently on
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For greater reliability of the threshold readings 
especially when values obtained were widely divergent 
on the same test point, suggesting that threshold was 
reported by the subject when he/she thought that 
stimulus had been applied rather than when he/she 
actually felt it, catch trials were done specifically for 
subjects with divergent readings at the same test point. 
Catch trials involved turning off the main Bio-
thesiometer switch without the subjects' knowledge 
while still applying the vibrator button. If he/she still 
reports sensation when stimulus had been switched off, 
it confirmed inappropriate response. The entire test 
procedure was re-explained to this category of patients 
to facilitate reliable cooperation and repeated.
VPT is the lowest threshold at which vibration is sensed 
on the pulp of the big toe and the value in normal 
subjects increases with age from approximately 6 volts 
31at age 30 years to 20 volts at age 75 years . Neuropathy 
was considered objectively present if the VPT was > 20 
volts in either foot.
Aesthesiometry was done using the Weinstein 
tmEnhanced Sensory Test 10gm  monofilament pressure 
32aesthesiometer (WEST FOOT)  sourced from 
Connecticut Bio-instruments Inc (CBI), 9 Golden 
Heights Road, Danbury, Connecticut, 06813 USA, to 
detect Loss of Protective Sensation (LOPS). This 
monofilament (MF) is a patented improvement of the 
classic Semmes Weinstein (SW) monofilaments from 
Semmes Weinstein Corporation and has the advantages 
of calibration for applied force. Calibration confers on 
the monofilaments the property of applying a single 
characteristic force without regard to the degree of bend 
or hand induced vibration thus improving sensitivity. It 
also has the advantage of improved specificity, 
inducing pressure, not pain. The classical SW MF tip is 
sharp (hence it's also referred to as right cylindrical or 
common tip MF) and inappropriately may stimulate 
pain receptors. The pain sensation stimulated can 
interfere with the measurement of tactile sensation and 
compromise accurate measurement of force sensation.
The WEST- foot MF tester has round textured tips (Sof 
tmTip ) and eliminates this confound from painful 
stimulation by presenting a stimulus that is non-noxious 
to the patient. 
Patients were tested lying supine on an examination 
couch and the MF applied to 8 sites - 4 in each foot - 
specifically the plantar surface of the hallux, the first, 
33third and fifth metatarsal heads.  
Prior to testing, the subject was familiarized with the 
test procedure. During testing with patient looking 
away from the foot being tested, the MF was slowly 
pressed onto the skin until it buckled (bent) 
oappropriately to <180 C and was held on the test site 
buckled for one second. This one-second application 
was approximated by silently saying one “Mississippi” 
and the MF then slowly raised from the skin to about 
1cm above the test site. This manoeuvre is important to 
eliminate the possibility of patient responding to false 
clues (non-tactile stimuli) such as visual clues from 
seeing motion from the investigators arm or trunk from 
in the study population.  
Table 2 shows the UKST signs score. The signs scored 
were ankle reflex, vibration, pinprick and temperature 
sensations. All sensations were tested at the pulp of the 
hallux. Vibration was assessed using a low frequency 
27(128Hz) tuning fork  and temperature tested by 
assessing the patients' response (cold, warm or unable 
to tell) to iced tuning fork (tuning fork inserted in ice-
blocked water for one minute) and placed on the pulp of 
9the hallux.  Temperature sense was scored as abnormal 
if the patient perceived the iced-tuning fork as warm or 
unable to tell. For all sensations, each foot was scored 
separately. Presence of normal sensations scores 0 
point, while reduced/absent sensations score 1 point for 
each foot. Normal reflexes score 0 point, presence with 
reinforcement 1 point and absence 2 points for each 
foot.
Maximum signs score was 10, graded as follows:
: Normal (no PN) 0-2
: Mild PN 3-5
: Moderate PN 6-8
: Severe PN 9-10
Using the signs score, PN was assessed as objectively 
present with moderate (6-8) or severe (9-10) signs 
score. Akin to the symptoms score, this criterion for 
diagnosing PN was chosen to eliminate the risk of 
overestimation by including mild signs scores that 
often normally occur in the general population with 
increasing age and potentially distorts the possible 
26relationship between diabetic neuropathy and age . 
Bio-Thesiometry was done using the model PVD-LP 
Bio-thesiometer from Bio-Medical Instrument 
28Company Ohio, USA.  This instrument objectively 
measures vibration sensation and determines the 
vibration perception threshold (VPT). Patients were 
tested lying supine on an examination couch and prior 
to testing, the procedure was explained and 
demonstrated to the patient for familiarization. Testing 
was commenced by applying the vibrator of the Bio-
thesiometer to the test site - the pulp of the big toe of 
each foot. This site is routinely used in screening tests to 
29detect PN.  The vibrator was held in such a way that the 
weight of the vibrator furnished a standard pressure on 
the vibrator button with the probe balanced vertically 
on the pulp of the great toe. 
The vibrator was held steady and the subject instructed 
to concentrate all attention at the test site and to verbally 
report the first appearance of the sensation of vibration 
by saying “yes”. The amplitude of the vibrator button 
was set as low as possible at the start of testing and 
increased until the patient perceived vibration. The 
voltage on the Bio-thesiometer display at that instant 
was recorded as Threshold 1 (TH ). This threshold is 1
usually higher than the actual threshold due to the 
reaction time of the patient. Two further threshold 
readings (TH  and TH ) were obtained at the test site 2 3
and the mean of the last two readings used to 
30determined the VPT for each foot.
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RESULTS
Among the 120 diabetic participants, 83 (69.2%) had 
neuropathic symptoms (the symptomatic group) while 
37(30.8%) were asymptomatic. Table 3 shows the 
socio-demographic characteristics of the participants. 
The age range for the symptomatic group was 40-78 
years and 30-76 years for the asymptomatic group. The 
mean age of the symptomatic group was 60+ or - 9.22 
years and 48.51 ± 15.35 years for the asymptomatic 
group. The difference in the mean ages of the two study 
groups was statistically significant (Z=5.26, df =118, 
p<0.05).
In the symptomatic group, 53(63.9%) were males while 
30(36.1%) were females and in the asymptomatic 
group, 20(54.1%) were males compared to 17(45.9%) 
females. The difference in the gender distribution of the 
two study groups was not statistically significant 
2(x =1.032. df =1, p =0.31). The majority of the 
symptomatic 71(85.5%) and asymptomatic 31(83.8%) 
participants had poor glycaemic control (venous fasting 
plasma glucose FPG=6.0 mmol/L) and the difference in 
the mean FPG for the symptomatic (12.9±5.4mmol/L) 
and asymptomatic (12.2±4.6mol/L) participants was 
not statistically significant (Z= 0.69, p = 0.495).  
Table 4 details the effect of duration of DM on 
peripheral neuropathy (PN) as diagnosed by the various 
methods for both study groups. All the diagnostic 
methods increasingly detected PN with increasing 
duration of DM. The UKST method detected PN least in 
those with duration of DM <5years and highest in those 
with duration of DM >15 years. For the symptomatic 
group, it detected PN in 73.9% of those with duration of 
DM <5 years and 100.0% in those with duration of DM 
>15 years. 
Table 1: The United Kingdom Screening Test (UKST): Symptom Score and Grading. 
 
their peripheral vision.
When the MF buckles appropriately, it exerts 10 grams 
of force and subject acknowledges perception of the 
MF application with a verbal response of “yes” during 
or immediately after the application while not looking 
at the foot. This confirms presence of protective 
sensation while absence of a “yes” response indicates 
LOPS, confirming presence of PN. The criterion for 
LOPS with one application of the MF was 0 of 1 
criterion, that is, zero detection with one application of 
the MF at any or all sites tested. Applications were not 
made to corns, calluses or scar tissues as these were 
3potential sites for false positive results.  For greater 
reliability, the order and timing of successive tests was 
randomized to reduce the potential for patient guessing 
and where the 0 of 1 criterion was inconclusive in 
defining LOPS, the 0 or 1 of 3 criterion was applied. By 
this criterion, LOPS was defined by 0 or 1 detection out 
of 3 applications of the MF and excluded by the 2 out of 
3 rule. By this rule, when testing one specific site, more 
than one detection of three applications of the MF 
excludes LOPS.
Overall PN was considered present (presence of LOPS) 
by failure to detect the MF application at 1 or more sites 
(0-3/4) in either foot and 0-7/8 in both feet. It was 
considered absent (absence of LOPS) with detection of 
the MF at all 4 sites (4/4) in each foot and 8/8 in both 
feet.
Statistical analysis was by SPSS (version 10) 
evaluating and presenting simple descriptive statistics. 
The mean, standard deviation and percentages of all 
data were derived. The Z test was used to determine the 
differences between the mean ages and glycaemic 
control of the two study groups while the Chi square test 
was used to evaluate the difference in the gender 
distribution of the symptomatic and asymptomatic 
study groups. p value of < or = 0.05 was taken to 
indicate statistical significance.
   
GRADE: 0-2 (Normal) No Peripheral Neuropathy
   3-4 Mild Peripheral Neuropathy
                 5-6        Moderate Peripheral Neuropathy
                 7-9        Severe Peripheral Neuropathy
             Symptom               Score 








  9 
1   Abnormal Sensations Felt -    Burning, Numbness Or Tingling 



















3   Time of Worst Symptoms      -      Night Only 
- Both Day And Night 










4. Alleviating Factor                -      Walking Around 
                                                    -      Standing 










5   Night- Time Awakening        -     Yes 
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DM <5 years and 100.0% in those with duration of DM   
>15 years. Similarly, Bio-thesiometry detected PN least 
in those with duration of DM <5 years and highest in 
those with duration of DM >15 years.  
For the symptomatic group, it detected PN in 47.8% of 
those with duration of DM <5 years and 100.0% of those 
with duration of DM >15 years. For the asymptomatic 
group, it detected PN in 16.7% of those with duration of 
DM <5 years and 100.0% in those with duration of DM 
>15 years.
GRADE: 0-2: (Normal) No Peripheral Neuropathy
   3-5: Mild Peripheral Neuropathy
                 6-8         Moderate peripheral neuropathy
                 9-10         Severe peripheral neuropathy
For the asymptomatic group, it detected PN in 25.0% of 
those with duration of DM <5 years and 100.0% in 
those with duration of DM >15 years. Aesthesiometry 
detected PN least in those with duration of DM <5 years 
and highest in those with duration of DM >15 years. 
For the symptomatic group, it detected PN in 65.2% of 
those with duration of DM <5 years and 91.7% of those 
with duration of DM >15 years. For the asymptomatic 
group, it detected PN in 29.2% of those with duration of 
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DISCUSSION
Over 120 million people in the world suffer from 
diabetes mellitus (DM) and many have diabetic foot 
ulcers (DFUs), which may eventually lead to an 
34amputation.  The costs associated with DFUs can be 
tremendous and remains a major burden to both the 
35,36patient and the health care system.  Studies from 
Nigeria and elsewhere consistently report that the 
diabetes mellitus foot syndrome (DMFS) is the single 
most common cause of prolonged hospitalization 
37,38amongst people with diabetes.  Thus, identification 
of the risk factors for foot ulceration is of paramount 
significance in the prevention of this enormous 
complication of DM. Several risk factors predispose 
the diabetic patient to foot ulceration with peripheral 
neuropathy and peripheral vascular disease being 
4major risk factors.  Other reported risk factors include 
foot deformity, previous history of foot ulceration or 
amputation, male gender, elderly age, poor glycaemic 
control, long duration of diabetes mellitus and poor foot 
3,39,40care.   
This study sought to evaluate the effect of duration of 
DM on peripheral neuropathy using the UKST scoring 
system, Bio-thesiometry and Aesthesiometry in 
Nigerian diabetic subjects without current or previous 
foot ulceration.  The participants were divided into two 
groups- those with symptoms of peripheral neuropathy 
(the symptomatic group) and those without symptoms 
of peripheral neuropathy (the asymptomatic group), 
using the UKST scoring system. The UKST is a two 
part diagnostic test comprising symptoms score and 
signs score and was used to determine the prevalence of 
PN in over six thousand diabetic patients in the United 
Kingdom. The symptoms score component of the 
UKST was used to separate the study population into 
two groups  those with symptoms of PN (the 
symptomatic group) and those without symptoms of 
Table 4: The Effect of Duration of Diabetes Mellitus on Peripheral Neuropathy as Diagnosed by Various 
Methods
PN (the asymptomatic group). This separation was 
necessary to compare the effect of these risk factors in 
the two groups as those with symptoms of peripheral 
neuropathy are supposedly at higher risk for DFU from 
PN compared to those without neuropathic symptoms. 
The results of our study disagreed with this empirical 
expectation and showed that the effect of long duration 
of diabetes mellitus on PN as a risk factor for foot 
ulceration in diabetic subjects was similar, irrespective 
of the presence or absence of neuropathic symptoms. 
Long duration of DM (>10 years) is a recognized risk 
1factor for foot ulceration in diabetic subjects.  Often, as 
in this study, it may not reflect the true duration of the 
disease, rather it reflects the time since diagnosis, as 
NIDDM onset may precede its diagnosis by several 
2years.  The effect of long duration of diabetes probably 
relates to increased production of glycosylation end 
41products.  The risk of amputation appears to parallel 
the prevalence of neuropathy, which increases with 
duration of DM. In general, for duration of DM up to or 
less than 10 years, the majority of patients do not have 
neuropathy, but for durations greater than 10 years,
4 majority of patients have neuropathy. In the Pima 
 2Indian Study,  duration of DM was a significant risk 
factor for amputation, even after controlling for age and 
sex.  
The findings of this study agrees with previous reports 
3,4,26 and showed clearly that both long duration of DM 
and PN are genuine risk factors for foot ulceration in 
diabetic subjects, irrespective of the presence or 
absence of the most alarming symptom of diabetic foot 
disease  peripheral neuropathy. The various methods for 
diagnosing PN positively diagnosed PN with increasing 
duration of diabetes, the highest diagnoses occurring in 
those with duration of DM >15 years, for both study 
populations. In this sub-group, the diagnosis of PN by 
the various methods for the symptomatic study group 
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Durati 
on                      UKST      Aesthesiometry Bio-Thesiometry
(Years)
Symptomatic     Asymptomatic         Symptomatic         Asymptomatic       Symptomatic    Asymptomatic         
                     (N83)          (N37)                          (N83)                     (N37)                          (N83)                 (N37)    
            
            Positive     Number  Positive        Number     Positive     Number  Positive     Number Positive      Number  Positive    Number 
            Diagnosis  Studied   Diagnosis     Studied      Diagnosis  Studied   Diagnosis  Studied   Diagnosis  Studied    Diagnosis Studied
                (%)                             (%)                                    (%)                             (%)                              (%)                         (%)
<5       17(73.9)    23           6(25.0)        24              15(65.2)    23           7(29.2)      24          11(47.8)     23            4(16.7)     24
5-10    19(90.5)    21           8(72.7)        11              14(66.7)    21           6(54.5)      11          10(47.6)     21            5(45.5)     11
11-15  15(100)     15           0 (0.0)          0               13(86.7)    15           0(0.0)        0             13(86.7)    15            0(0.0)       0
>15     24(100)     24           2(100)          2               22(91.7)    24           2(100)       2             24(100)     24            2(100)      2
Total   75(90.4)   83           16(43.2)       37              64(77.1)    83          15(40.5)    37           58(69.9)    83            11(29.7)    37
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was 100.0% (UKST), 91.7% (Aesthesiometry), and 
100.0% (Bio-thesiometry), and for the asymptomatic 
g roup ,  i t  was  100 .0% (UKST) ,  100 .0% 
(Aesthesiometry), and 100.0% (Bio-thesiometry).  
Positive diagnosis of PN for those with duration of DM 
<5 years by all methods was lower.  
In this sub-group, the diagnosis of PN by the various 
methods for the symptomatic study group was 73.9% 
(UKST), 65.2% (Aesthesiometry), and 47.8% (Bio-
thesiometry), and for the asymptomatic group, it was 
25.0% (UKST), 29.2% (Aesthesiometry), and 16.7% 
(Bio-thesiometry). These findings show that as the 
duration of diabetes increased, the risk for developing 
PN and subsequently diabetic foot disease also 
increased, even in those without symptoms of PN. 
CONCLUSION
Considering the heavy financial, physical and 
emotional burden to the patient (and the health care 
system) associated with diabetic foot complications, 
identification of the risk factors for foot ulceration 
remains of paramount significance in the prevention of 
this dreaded complication of diabetes mellitus. Diabetic 
42patients with lengthy duration (>10 years) of diabetes  
are at high risk for foot complications from DM and 
need enrollment into effective preventive programmes 
for foot disease to reduce the rate of avoidable loss of 
limbs to diabetes.
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